One-year safety of ibuprofen/famotidine fixed combination versus ibuprofen alone: pooled analyses of two 24-week randomized, double-blind trials and a follow-on extension

References

• Paulose-Ram R, Hirsch R, Dillon C, et al. Prescription and non-prescription analgesic use among the US adult population: results from the third National Health and Nutrition Examination Survey (NHANES III). Pharmacoepidemiol Drug Saf 2003;12:315-26
   PubMed Web of Science ®Google Scholar
• Derry C, Derry S, Moore RA, McQuay HJ. Single dose oral ibuprofen for acute postoperative pain in adults. Cochrane Database Syst Rev 2009;3:CD001548
   Google Scholar
• Lee P, Anderson JA, Miller J, et al. Evaluation of analgesic action and efficacy of antirheumatic drugs. Study of 10 drugs in 684 patients with rheumatoid arthritis. J Rheumatol 1976;3:283-94
   PubMed Web of Science ®Google Scholar
• Coxib and traditional NSAID Trialists’ (CNT) Collaboration, Bhala N, Emberson J, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual patient data from randomized trials. Lancet 2013;382:769-79
   PubMed Web of Science ®Google Scholar
• Laine L. GI risk and risk factors of NSAIDs. J Cardiovasc Pharmacol 2006;47(Suppl 1):S60-6
   PubMed Web of Science ®Google Scholar
• Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987;82:1153-8
   PubMed Web of Science ®Google Scholar
• Bello AE, Kent JD, Grahn AY, et al. Risk of upper gastrointestinal ulcers in patients with osteoarthritis receiving single-tablet ibuprofen/famotidine versus ibuprofen alone: pooled efficacy and safety analyses of two randomized, double-blind, comparison trials. Postgrad Med 2014;126:82-91
   PubMed Web of Science ®Google Scholar
• Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. New Engl J Med 2005;52:1092-102
   Google Scholar
• Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. New Engl J Med 2005;352:1071-80
   PubMed Web of Science ®Google Scholar
• COX-2 selective (includes Bextra, Celebrex, and Vioxx) and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). FDA Postmarket Drug Safety Information for Patients and Providers. Washington, DC: FDA, 7 April 2005. Available at: http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm103420.htm [Last accessed 21 October 2014]
   Google Scholar
• Salvo F, Antoniazzi S, Duong M, et al. Cardiovascular events associated with the long-term use of NSAIDs: a review of randomized controlled trials and observational studies. Expert Opin Drug Saf 2014;13:573-85
   PubMed Web of Science ®Google Scholar
• February 10–11, 2014: Joint meeting of the Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee meeting announcement. FDA Advisory Committee Calendar. Washington, DC: FDA, 8 January 2014. Available at: http://www.fda.gov/AdvisoryCommittees/Calendar/ucm380871.htm [Last accessed 21 October 2014]
   Google Scholar
• Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002;(Issue 4):CD002296
   Google Scholar
• Merck Sharpe & Dohme. Pepcid prescribing information. West Point, PA, USA: Merck Sharpe & Dohme, 1986
   Google Scholar
• Smith JL, Gamal MA, Chremos MA, Graham DY. Famotidine, a new H2-receptor antagonist. Effect on parietal, nonparietal, and pepsin secretion in man. Dig Dis Sci 1985;30:308-12
   PubMed Web of Science ®Google Scholar
• Takeda T, Yamashita Y, Mitsui Y, Shimazaki S. Histamine decrease the permeability of an endothelial cell monolayer to dextran: preliminary report. J Japan Surgical Assoc 1992;93:1513
   PubMedGoogle Scholar
• Schunack W. Pharmacology of H2-receptor antagonists: an overview. J Int Med Res 1989;17(Suppl 1):9-16A
   Google Scholar
• Kent JD, Holt RJ, Jong D, et al. Pharmacodynamic evaluation of intragastric pH and implications for famotidine dosing in the prophylaxis of non-steroidal anti-inflammatory drug induced gastropathy – a proof of concept analysis. J Drug Assess 2014;3:20-7
   PubMedGoogle Scholar
• Hudson N, Taha AS, Russell RI, et al. Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. Gastroenterology 1997;112:1817-22
   PubMed Web of Science ®Google Scholar
• Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal anti-inflammatory drugs. N Engl J Med 1996;334:1435-9
   PubMed Web of Science ®Google Scholar
• Corleto VS, Festa S, Di Giulio E, Annibale B. Proton pump therapy and potential long-term harm. Curr Opin Endocrinol Diabetes Obes 2014;32:3-8
   Google Scholar
• Moore A, Makinson G, Li C. Patient-level pooled analysis of adjudicated gastrointestinal outcomes in celecoxib clinical trials: meta-analysis of 51,000 patients enrolled in 52 randomized trials. Arthritis Res Ther 2013;15:R6
   Google Scholar
• Updated safety information about a drug interaction between clopidogrel bisulfate (marketed as Plavix) and omeprazole (marketed as Prilosec and Prilosec OTC). FDA Public Health Advisory. Washington, DC: FDA/Center for Drug Evaluation and Research, 17 November 2009. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm190825.htm [Last accessed 2 April 2014]
   Google Scholar
• Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009;301:937-44
   PubMed Web of Science ®Google Scholar
• Khalique SC, Cheng-Lai A. Drug interaction between clopidogrel and proton pump inhibitors. Cardiol Rev 2009;17:198-200
   PubMed Web of Science ®Google Scholar
• Targownik LE, Metge CJ, Leung S, Chateau DG. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Gastroenterology 2008;134:937-44
   PubMed Web of Science ®Google Scholar
• Pfizer. Motrin prescribing information. New York, NY, USA: Pfizer Inc., 2007
   Google Scholar
• Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713-19
   PubMed Web of Science ®Google Scholar
• Horizon. Duexis prescribing information. Deerfield, IL, USA: Horizon Pharma USA Inc., 2012
   Google Scholar
• Laine L, Kivitz AJ, Bello AE, et al., on behalf of the REDUCE-1 and -2 Study Investigators. Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs ibuprofen alone for reduction of gastric and duodenal ulcers. Am J Gastroenterol 2012;107:379-86
   PubMed Web of Science ®Google Scholar
• Schiff M, Peura D. HZT-501 (Duexis; ibuprofen 800 mg/famotidine 26.6 mg) GI protection in the treatment of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Exp Rev Gastroenterol Hepatol 2012;6:25-35
   PubMed Web of Science ®Google Scholar
• Merck & Co. Inc. Pepcid prescribing information. Whitehouse Station, NJ, USA: Merck & Co., 2007
   Google Scholar
• Bello AE, Holt RJ. Cardiovascular risk with non-steroidal anti-inflammatory drugs: clinical implications. Invited commentary. Drug Saf 2014;37:897-902
   Google Scholar
• Goldstein JL, Hochberg MC, Fort JG, et al. Clinical trial: the incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric-coated naproxen alone. Aliment Pharmcol Ther 2010;32:401-13
   PubMed Web of Science ®Google Scholar
• Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 2002;325:1-8
   PubMedGoogle Scholar
• Bavry AA, Fridtjof T, Allison M, et al. Nonsteroidal anti-inflammatory drugs and cardiovascular outcomes in women: results from the Women’s Health Initiative. Circ Cardiovasc Qual Outcomes 2014;7:603-10
   PubMed Web of Science ®Google Scholar
• Antman EM, Bennet JS, Daugherty A, et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007;115:1634-42
   PubMed Web of Science ®Google Scholar
• Manavathongcha S, Bian A, Rho YH, et al. Inflammation and hypertension in rheumatoid arthritis. J Rheum 2013;40:1806-11
   PubMed Web of Science ®Google Scholar
• Lindhardsen J, Gislason GH, Jacobsen S, et al. Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis 2014;73:1515-21
   PubMed Web of Science ®Google Scholar
• Deeks ED. Fixed-dose ibuprofen/damotidine: a review of its use to reduce the risk of gastric and duodenal ulcers in patients requiring NSAID therapy. Clin Drug Investig 2013;33:1173-2563
   Google Scholar